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Summary  
 
Increased protein synthesis plays an etiologic role in diverse cancers. Here we demonstrate that 
METTL13 (methyltransferase-like 13) dimethylation of eEF1A (eukaryotic elongation factor 
1A) lysine 55 (eEF1AK55me2) is utilized by Ras-driven cancers to increase translational output 
and promote tumorigenesis in vivo. METTL13-catalyzed eEF1A methylation increases eEF1A’s 
intrinsic GTPase activity in vitro and protein production in cells. METTL13 and eEF1AK55me2 
levels are upregulated in cancer and negatively correlate with pancreatic and lung cancer patient 
survival. METTL13 deletion and eEF1AK55me2 loss dramatically reduce Ras-driven neoplastic 
growth in mouse models and in patient-derived xenografts (PDX) from primary pancreatic and 
lung tumors. Finally, METTL13 depletion renders PDX tumors hypersensitive to drugs that 
target growth-signaling pathways. Together, our work uncovers a mechanism by which lethal 
cancers become dependent on the METTL13-eEF1AK55me2 axis to meet their elevated protein 
synthesis requirement and suggests that METTL13 inhibition may constitute a targetable 
vulnerability of tumors driven by aberrant Ras-signaling. 
 
 
 
 
 
 
 
Keywords: METTL13, eEF1A, lysine methylation, RAS, protein methylation, translation, 
translation elongation, pancreatic cancer, lung cancer  
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Introduction 
 
Lysine methylation is the addition of one, two or three methyl groups to the ε-nitrogen of a 
lysine sidechain, forming mono-, di-, and tri-methylated derivatives (referred to here as me1, 
me2, and me3, respectively). The chemical addition of methyl moieties to lysine residues is 
catalyzed by lysine methyltransferases (KMTs). Biological functions for lysine methylation is 
best characterized on histone proteins and the regulation of epigenetics and chromatin biology 
(Chi et al., 2010). Beyond histones, there is a growing appreciation that a number of non-histone 
proteins (e.g. p53, RB, RelA) are modulated by lysine methylation (Carlson and Gozani, 2016). 
In the human proteome there are predicted to be greater than 100 KMTs that belong to one of two 
protein methylase families: SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain enzymes and 
7βS (seven-β-strand) enzymes (Clarke, 2013). All of the validated histone KMTs reside within 
the SET domain family with the exception of the H3K79 KMT hDOT1L, which belongs to the 
7βS family. Several additional SET and 7βS enzymes methylate non-histone proteins to 
influence different nuclear and cytoplasmic activities; however, the biological function, catalytic 
activity and substrate specificity for the majority of the large family of 7βS KMTs remains to be 
elucidated (Carlson and Gozani, 2016). 
The GTPase eEF1A (eukaryotic elongation factor 1 alpha) is an evolutionarily conserved and 
fundamental non-ribosomal component of the translational machinery and one of the most 
abundant proteins found in eukaryotic proteomes (Schuller and Green, 2018). Methylation of 
eEF1A occurs at several lysine residues, many of which are conserved from yeast to humans 
(Hamey and Wilkins, 2018; Jakobsson et al., 2018a). Further, it has been suggested that akin to 
the extensive role histone methylation plays in chromatin regulation, eEF1A methylation may 
likewise regulate distinct eEF1A-mediated biology, including translation elongation. In humans, 
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there are two eEF1A paralogs, eEF1A1 and eEF1A2, which are 90% identical and 98% similar. 
The expression of eEF1A1 is ubiquitous while eEF1A2 expression is limited largely to post-
mitotic cells (e.g. neurons and cardiomyocytes) (Lee and Surh, 2009). However, eEF1A2 
expression is re-activated in cancers and eEF1A1 levels are generally higher in neoplastic 
relative to normal tissues (Lee and Surh, 2009). Furthermore, cancers that are driven by PI3K-
AKT activation show increased sensitivity to eEF1A inhibitors (Lee and Surh, 2009). 
Connections between mRNA translation and cancer are well-established whereby it is postulated 
that alterations in the components of the translation apparatus, including eEF1A1/2 
overexpression, may be required to fuel neoplastic growth downstream of oncogenic RAS-
MAPK and PI3K-AKT signaling, which frequently drive lethal neoplasms including lung and 
pancreatic cancer (Bhat et al., 2015; Robichaud et al., 2018; Truitt and Ruggero, 2016).  
Lung cancer is the most common cause of global cancer-related mortality, leading to over a 
million deaths each year, and lung adenocarcinoma (LAC) is the most common histological type. 
Most LAC cases are due to oncogenic KRAS and/or additional mutations that are to date 
unfortunately not clinically actionable. Pancreatic cancer is also a lethal malignancy. More than 
75% of patients die within the first twelve months of diagnosis; the five-year survival rate is 
below 5%. Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent pancreatic cancer 
subtype. It typically presents at an advanced stage and is refractory to most treatment modalities. 
The vast majority of PDAC cases express oncogenic mutant KRAS (Almoguera et al., 1988). 
Due to the lethality of LAC and PDAC, the fundamental role of the KRAS pathway, and the 
difficulty in directly inhibiting KRAS, drug discovery efforts have turned to inhibiting 
downstream kinase targets (e.g. RAF, MEK1/2 and ERK1/2) and Ras-activated pathways (e.g. 
PI3K). While compounds that inhibit these kinases have shown promise in cell culture and 
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animal experiments, clinical studies have been less encouraging due to toxicity and the 
development of therapy resistance (Infante et al., 2014). Thus, there is great interest in 
identifying factors that cooperate with the canonical KRAS pathway to drive cancer with the 
hope that a therapeutic strategy hitting multiple pathways will hinder resistance development, 
while also mitigating toxicity by lowering the overall dose needed for each medicine.  
In this work, we find that di-methylation of eEF1A at lysine 55 (eEF1AK55me2) is a high 
stoichiometry species that is upregulated in pancreatic and lung cancers and associated with poor 
clinical outcomes. In a genetic screen we identify the orphan protein METTL13 as the 
physiologic enzyme specifically tasked with generating eEF1AK55me2. Notably, METTL13 
expression is also upregulated in cancer wherein it negatively correlates with patient survival. 
We demonstrate that METTL13, via eEF1AK55 methylation, regulates protein synthesis in 
cancer cells. Further, METTL13 depletion inhibits proliferation of several cancer cell lines and 
significantly reduces tumorigenesis in vivo in Ras-driven pancreatic and lung cancer mouse 
models and in patient-derived xenograft models from human pancreatic and lung cancers. 
Finally, we show that METTL13 depletion markedly sensitizes cancer cells and xenograft 
tumors to drugs that target growth-signaling pathways. Together, our data support a model in 
which regulation of translation elongation by the METTL13-eEF1AK55me2 axis serves as a 
mechanism utilized by malignancies to adapt to their increased translational requirements.  
 
 
 
RESULTS 
 
Identification of the orphan gene METTL13 as a candidate eEF1A lysine 55 
dimethyltransferase 
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The methylation of eEF1A is conserved from yeast to humans, suggesting that akin to 
histone methylation, a modification network may regulate specific eEF1A functions (Hamey and 
Wilkins, 2018; Jakobsson et al., 2018a). While several conserved enzymes that methylate 
different residues on eEF1A have been identified, the KMT responsible for generating 
methylation of eEF1A at lysine 55 (eEF1AK55me), a modification that is present in humans but 
not detected in yeast, is not known (Figure 1A). We analyzed methylation of eEF1A purified 
from seven cell lines by liquid chromatography tandem mass spectrometry (LC-MS/MS) and 
found that >98% of eEF1A1/2 molecules harbor di-methylation at K55, with a small fraction of 
K55 being unmodified or bearing mono-methylation (Figure 1B and S1A-B). Next, we raised 
state-specific eEF1AK55me1-3 antibodies and found that each antibody selectively recognized 
its own state of methylation on eEF1A peptides (Figure 1C and S1C). In addition, the anti-
eEF1AK55me2 antibody selectively recognized eEF1AK55me2 peptides, as it did not bind to 19 
different peptides from other proteins that harbour a dimethyl lysine (Figure S1D).  
To discover the enzyme that generates the eEF1AK55me2 mark, we used a gene editing 
coupled biochemical screening strategy (see schematic, Figure 1D). 107 known and putative 
KMTs in the human genome were identified and a focused CRISPR/Cas9 knockout collection 
was generated consisting of 3 independent small guide RNAs (sgRNA) per KMT gene and one 
control sgRNA for a total of 322 sgRNAs (Table S1). The collection was used to generate 322 
individual U2OS cell lines, each expressing a single sgRNA from the collection. Lysates were 
prepared from each individual cell line to generate a collection of 322 unique lysates, which were 
systematically probed with the eEF1AK55me2 antibody to determine gene(s) whose deletion 
results in loss of the eEF1A methylation signal (Figure 1D; for control lysate see Figure S1E). 
Strikingly, out of the 107 potential KMTs that were targeted by sgRNAs, abrogating METTL13 
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expression was the only intervention that reduced eEF1AK55me2 signal (Figure S1E-F). 
Notably, two sgRNAs (METTL13-b and -c) reduced METTL13 protein levels, which was 
paralleled by a decrease in eEF1AK55me2 signal, whereas cells expressing the METTL13-a 
sgRNA retained METTL13 expression and failed to reduce eEF1AK55me2 signal (Figure 1E). 
These results suggest that out of 107 potential KMTs in the human genome, only METTL13, an 
uncharacterized member of the 7βS family, regulates eEF1AK55 dimethylation in U2OS cells.  
 
The principal physiologic activity of METTL13 is generation of eEF1AK55me2 
In in vitro methylation assays using recombinant proteins with 3H-SAM (S-adenosyl-
methionine) as the methyl donor, METTL13 methylated GST-eEF1A1 and GST-eEF1A2, but 
not eEF1A1/2 proteins harboring a K55R substitution (Figure 2A). We also performed in vitro 
methylation reactions with non-radiolabeled SAM and observed METTL13 mono- and di-
methylation (but not tri-methylation) of eEF1A1/2 at K55 by Western blotting (Figure 2B) and 
LC-MS/MS (Figure S2A-B).  
METTL13 contains two putative methyltransferase (MTase) domains, one at the N-terminus 
and one at the C-terminus (top panel, Figure 2C). The N-terminal MTase 1 domain is necessary 
for METTL13 methylation of GST-eEF1AK55, whereas the C-terminal domain is dispensable 
for this activity (Figure 2C). Structure-function analysis identified residues 1-401 of METTL13 
as sufficient for eEF1AK55 methylation activity, as further C-terminal deletions were not 
tolerated (Figure 2D). Using a combination of structural modelling (Figure S2C) and sequence 
homology to other 7βS KMTs (Figure S2D), we identified several specific substitutions that 
abrogated METTL13’s catalytic activity (Figure S2D), including G58R, which is predicted to 
interfere with SAM binding (Figure 2E and S2C).  
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In addition to U2OS cells (see Figure 1E), we found that depletion of METTL13 by two 
independent sgRNAs (targeting exon-intron junctions and named METTL13-1 and METTL13-2) 
resulted in loss of eEF1AK55me2 in six additional cell lines as determined by Western blotting 
(Figure 3A; LC-MS/MS shown in Figure S3A). Complementation of METTL13-depleted NCI-
H2170 cells with CRISPR-resistant wild-type METTL13, but not the catalytic-dead 
METTL13G58R, restored eEF1AK55me2 levels (Figure 3B). Collectively, these results identify 
METTL13 as a bona fide KMT that methylates eEF1A at K55 in vitro and is required for 
maintenance of physiologic levels of eEF1AK55me2 in cells in a catalytic activity-dependent 
manner.    
eEF1A is one of the more abundant proteins in the human proteome and K55me2 is a high-
stoichiometry event (Hamey and Wilkins, 2018; Jakobsson et al., 2018a) (Figure 1B). Based on 
our screen (Figure S1F) and cellular depletion studies (Figure 3A), our data argue that 
METTL13 is the principal enzyme tasked with generating physiologic eEF1AK55me2. This 
raises the question of whether the converse is true: is eEF1AK55 the only METTL13 substrate or 
one of many relevant substrates? Histones are heavily methylated and there are many enzymes 
that function as histone KMTs (Murn and Shi, 2017). However, in vitro, METTL13 does not 
methylate the four core histones (H3, H2A, H2B, and H4) or nucleosomes (Figure 3C). In 
addition, METTL13 does not methylate any proteins present in the 40S and 60S ribosomal 
subunits and 80S ribosomes that lack eEF1A (Figures 3D and S3B). To investigate METTL13 
catalytic specificity in a physiologic and unbiased setting, we used quantitative proteomics to 
compare the methylome of the PDAC cell line T3M4 ±METTL13 (Figure 3E). Of the >1000 
methylation events detected in the analysis, eEF1AK55 methylation (me1 and me2) were the 
only modifications quantitatively altered upon METTL13 depletion; no changes were observed 
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in histone methylation or for other eEF1A methylated residues (Figure 3E; Table S2). Structural 
modeling of the METTL13 catalytic core showed a distinct substrate recognition domain (Figure 
S2C), which is reminiscent of PrmA, a bacterial lysine methyltransferase that achieves substrate 
specificity through a conformation-specific enzyme-substrate interaction (Demirci et al., 2007). 
Indeed, METTL13 requires full-length eEF1A and is not active on an eEF1A peptide spanning 
K55 of eEF1A (Figure S3C), suggesting that it employs a three-dimensional topological 
substrate recognition mechanism similar to that of PrmA. Taken together, these results indicate 
that the principal physiologic catalytic activity of METTL13 is eEF1AK55 methylation (see 
Discussion).  
 
METTL13 and eEF1AK55me2 are highly expressed in pancreatic cancer and promote 
proliferation of pancreatic cancer cells.  
A meta-analysis of six publicly available human PDAC datasets showed consistent up-
regulation of METTL13 mRNA levels and a significant negative correlation between high 
METTL13 expression and PDAC patient survival (Figures S4A-B). Moreover, while METTL13 
protein expression was largely undetected by immunohistochemistry (IHC) in the normal 
pancreas, it was clearly observed in sections from murine and human PDAC samples (Figure 4A 
and S4C). IHC analysis of eEF1AK55me2 signal also showed a similar pattern, with low signal 
in normal pancreas and a strong signal in adjacent malignant tissue (Figure 4A and S4C). 
Further, both METTL13 and eEF1AK55me2 immunostaining signals on PDAC patient tissue 
arrays showed significant correlation with poor patient survival (Figure 4B-C). Similar results 
were observed for METTL13 expression and eEF1AK55me2 signal in lung cancer (Figures 
S4D-F). Consistent with these results, there is a strong correlation between METTL13 and 
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eEF1AK55me2 protein levels in both cancer types (Figure 4D). Finally, METTL13 and 
eEF1AK55me2 (and total eEF1A) levels are all elevated in pancreatic and lung cancer cell lines 
compared to the non-transformed IMR-90 and RPE-1 cell lines (Figure 4E).  
Our observations suggest a potential role for METTL13 and eEF1AK55me2 in oncogenesis. 
In this regard, depletion of METTL13 had no impact on proliferation of the non-transformed 
RPE-1 cell line (Figure 4F) but inhibited proliferation of the PDAC T3M4 cell line (Figure 4G) 
and six additional pancreatic, lung and other cancer cell lines (Figure S4G). The reduction in 
proliferation upon METTL13 depletion in T3M4 cells was rescued by complementation with 
CRISPR-resistant ectopic wild-type METTL13, but not by complementation with catalytically 
inactive METTL13G58R (Figure 4H). Our results implicate METTL13 methylation of eEF1AK55 
in PDAC cell proliferation. We next wanted to independently test the role of eEF1AK55 in the 
regulation of T3M4 cell proliferation. Since the highly abundant eEF1A1 isoform of eEF1A is 
essential for mRNA translation and eEF1A2 expression is re-activated in cancers, we focused on 
testing K55 in the context of eEF1A2 function in proliferation. Depletion of eEF1A2 led to a 
moderate reduction in overall eEF1AK55me2 levels (with the likely remaining signal being 
chiefly eEF1A1K55me2) and moderately attenuated proliferation of T3M4 cells (Figure 4I). 
Complementation with wild-type eEF1A2, but not eEF1A2 harboring a K55R substitution 
(eEF1A2K55R), was able to fully restore cancer cell proliferation (Figure 4I). Together these data 
argue that METTL13 regulates the proliferation of pancreatic cancer cells via di-methylation of 
eEF1AK55. 
 
Methylation regulates eEF1A GTPase activity and mRNA translation in cells 
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Since K55 of eEF1A is located on the catalytic surface of the eEF1A GTPase domain, we 
investigated the possibility that methylation may modulate its GTPase activity. To this end, 
recombinant Flag-tagged eEF1A proteins ±K55me were purified from either METTL13-
overexpressing 293T cells or METTL13-depleted 293T cells expressing METTL13G58R (leading 
to virtually complete loss of K55 methylation) (Figures 5A and S5A). We performed in vitro 
GTP hydrolysis assays to determine Michaelis-Menten kinetic properties of purified eEF1A 
proteins ± K55me2 (Figure S5B). The catalytic efficiency (kcat/KM) of eEF1A was ~20% higher 
in the K55 methylated state relative to the unmethylated state (Figure 5B and S5B), due to an 
increase in Vmax with no change in the Michaelis constant (Figure 5B). Notwithstanding that K55 
dimethylation increased basal GTPase activity of eEF1A, aminoacyl-tRNAs (aa-tRNAs) 
stimulation of eEF1A GTPase activity did not depend on the K55 methylation status (Cavallius 
and Merrick, 1998; Van Noort et al., 1986) (Figure S5C). Though upon aa-tRNA stimulation, 
GTPase activity of K55 dimethylated eEF1A remained higher as compared to K55 methylation 
deficient eEF1A (Figure S5C). These results suggest that METTL13-depenent eEF1A K55 
dimethylation increases its GTPase activity, which may boost translation elongation and thereby 
increase protein synthesis.   
To analyze the impact of eEF1AK55me2 depletion on mRNA translation we performed 
polysome profiling experiments on extracts from T3M4 cells ± METTL13 (Gandin et al., 2014). 
An accumulation of heavy polysomes and a decrease in light polysomes was observed in cells 
depleted of METTL13 relative to control cells (Figures 5C and S5D). An elevated heavy/light 
polysome ratio may reflect (i) increase in translation initiation which results in an engagement of 
a higher number of ribosomes into polysomes thereby suggesting upregulation of protein 
synthesis or (ii) downregulation of protein synthesis due to the reduction in elongation rates 
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which lead to protracted occupancy and stalling of polysomes on mRNA. Since these scenarios 
are expected to have opposing effects on mRNA translation rates, we directly measured protein 
synthesis using surface sensing of translation (SUnSET) (a method for monitoring global protein 
synthesis through detection of puromycin-labeled neosynthesized proteins (Schmidt et al., 
2009)), in pancreatic (T3M4) and lung (NCI-H2170) cancer cell lines ±METTL13 (Figures 5D-
E). In both cancer cell lines, METTL13 depletion decreased global protein synthesis, which was 
most evident after serum re-feeding of serum-starved cells wherein protein synthesis is acutely 
stimulated. In contrast, METTL13 depletion had no impact on global protein synthesis in the 
non-transformed RPE-1 cell line irrespective of conditions (Figure S5E). To avoid potential 
biases associated with puromycylation approaches, we pulsed cells with the methionine analog 
L-azidohomoalanine (AHA) (Iwasaki and Ingolia, 2017). When incorporated into newly 
synthesized proteins, the analog can be detected with streptavidin by first clicking the azide 
group of AHA to biotin-alkyne. The AHA incorporation assays mirrored results obtained by 
SUnSET in T3M4 cells (Figure 5F). Moreover, reconstitution of METTL13-depleted T3M4 cells 
with wild-type METTL13 restored protein synthesis levels to those observed in the control, 
whereas complementation with catalytic-dead METTL13G58R failed to do so (Figure 5G). 
Finally, depletion of eEF1A1 and eEF1A2, which as expected resulted in decreased protein 
synthesis of serum-stimulated cells, was partially rescued by complementation with wild-type 
eEF1A2, but not with the K55R eEF1A2 mutant (Figure S5F). These data suggest that consistent 
with its effect on proliferation, eEF1AK55 methylation by METTL13 stimulates protein 
synthesis in pancreatic cancer cells. 
 
METTL13 ablation inhibits Ras-driven tumorigenesis 
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METTL13 and eEF1AK55me2 levels negatively correlate with PDAC patient survival, while 
stimulating processes required for neoplastic growth (i.e. protein synthesis and proliferation). To 
directly test the role of METTL13 in Ras-driven PDAC, we first generated conditional 
Mettl13loxP/loxP mutant mice, which develop normally, are viable, and fertile (Figure S6A-B). 
Deletion of Mettl13 specifically in the pancreas of mice using a pancreas-specific Cre-
recombinase expressing strain Ptf1aCre/+ (Kawaguchi et al., 2002) resulted in no apparent 
developmental consequences and no evident physiological defects (data not shown).  
Acinar-to-ductal metaplasia (ADM) is an early step in PDAC initiation triggered by KRAS 
activating mutations (Crawford et al., 2002; Kanda et al., 2012). Using an ex vivo 3D culture 
system in which EGF stimulated RAS activation induces ADM (Guerra et al., 2003; Zhu et al., 
2007), as well as Mettl13 expression (Figure S6B), we found that Mettl13 deletion inhibited the 
appearance of duct-like structures (Figure S6C-E). To further investigate the role of METTL13 
in KRAS-driven PDAC, Mettl13 mutant mice were crossed to mice harboring a loxP-Stop-loxP 
KrasG12D knock-in allele (KrasLSL-G12D/+, hereafter Kras) (Hingorani et al., 2003), which allows 
for the controlled induction of oncogenic KRAS and the initiation of cancer. In vivo, ADM and 
PDAC initiation can be triggered in young Kras mutant mice by inducing severe acute 
pancreatitis via repeated injections of caerulein (Lee and Bar-Sagi, 2010; Morris et al., 2010) 
(see schematic Figure 6A). In this system, deletion of Mettl13, which led to complete loss of 
eEF1AK55me2 (Figure 6C and 6E), greatly reduced the appearance of pancreatic intra-epithelial 
neoplasia (PanIN) brought on by Kras activation (Figure 6D), as assessed by histopathological 
analysis and decreased signals for MUC5 (a marker of PanINs) and Ki67 (proliferation marker) 
(Figure 6B-E). These data suggest that METTL13 is required for efficient initiation of pancreatic 
cancer by oncogenic KRAS. 
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To study pancreatic tumor development and to perform survival studies, we used the 
Ptf1a+/Cre;Kras+/LSL-G12D;p53loxP/loxP (Kras;p53) mutant model in which PDAC develops with 
100% penetrance 6-8 weeks after birth (Bardeesy et al., 2006). In this aggressive malignancy 
model, Mettl13 deletion extended median survival by 60% relative to controls – from 54 days to 
86 days (Figure 6F). Accordingly, MRI revealed that tumor volumes in METTL13 knockouts 
were roughly reduced by 2/3 as compared to the age-matched control mice (Figure 6G-H) 
(Mazur et al., 2015). Finally, at autopsy, pancreatic tissue from Kras;p53 mutant mice is entirely 
occupied by transformed cells, whereas in Kras;p53;Mettl13 mutant mice areas of normal 
pancreatic tissue remain with overall decreased proliferation (Ki67) (Figure 6I-J). Together these 
data support a key in vivo role for METTL13 in oncogenic KRAS-driven pancreatic 
tumorigenesis. 
METTL13 and eEF1A are also potentially involved in lung adenocarcinoma (Figures S4D-F), 
a cancer in which Ras is frequently activated (Cancer Genome Atlas Research, 2014). We tested 
METTL13 function in LAC by intratracheal injection of an adenovirus expressing the Cre 
recombinase (Ad-Cre) in adult Kras+/LSL-G12D (Kras) and Kras+/LSL-G12D;Mettl13loxP/loxP 
(Kras;Mettl13) mice. As expected Kras mutant mice developed widespread adenocarcinoma at 
16 weeks after Ad-Cre infection (Jackson et al., 2001; Johnson et al., 2001), which was clearly 
visible at the whole organ level and by histopathology (Figure 6K). Strikingly, this was 
paralleled by the upregulation of METTL13 and eEF1AK55me2 (Figure 6K). In contrast 
Kras;Mettl13 mutant mice, which are devoid of eEF1AK55me2 (Figure 6K), tumor development 
was dramatically attenuated based on gross observation, quantification of tumor number and 
burden, and cell proliferation analysis by phospho-Histone H3 immunostaining (Figure 6K-L). 
Of note, a substantial fraction of tumors that emerged in the LAC model retained METTL13 
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expression and eEF1A methylation as assessed by IHC, suggesting incomplete bi-allelic Cre 
recombination in these clonal growths (Figure S6F) (Jackson et al., 2001; Liu et al., 2010). 
Together, these in vivo data indicate a central role for METTL13 in carcinogenesis of Ras-driven 
epithelial tumors of the pancreas and lung. 
Next, we investigated the role of METTL13-eEF1AK55me2 in human cancers using PDAC 
and LAC patient-derived xenograft (PDX) models. First, we performed ex vivo complementation 
to knockdown endogenous METTL13 and deplete eEF1AK55me2, and then reconstituted 
samples with either wild-type or catalytic-dead METTL13 using multiple independent PDXs 
from both cancers types (Figures 7A-B, S7A-B). The depletion of METTL13 attenuated 
xenograft tumor growth in both PDAC and LAC models (Figures 7A-B, S7A-B). 
Complementation with wild-type METTL13, which restored eEF1AK55me2 levels close to the 
levels of control cells, also reestablished tumor growth (Figures 7A-B, S7A-B). In contrast, 
reconstitution with METT13G58R did not rescue tumor growth (Figures 7A-B, S7A-B). These 
data suggest that the pro-tumorigenic functions of METTL13 require its catalytic activity.   
A feature of cancers triggered by oncogenes such as KRAS is up-regulation of protein 
synthesis (Bhat et al., 2015; Robichaud et al., 2018; Truitt and Ruggero, 2016). We postulated 
that one mechanism by which this may be achieved is through the METTL13-eEF1AK55me2 
axis. This led us to speculate that inhibiting METTL13 may cooperate with compounds targeting 
growth-signaling, which renders malignant cells addicted to increased protein synthesis. To test 
this idea, a comparative cell-based screen using a library assembled of 285 characterized 
inhibitors covering ~170 cancer targets (Table S3) was performed to identify drugs that have 
increased efficacy against T3M4 pancreatic cancer cells in the absence of METTL13. Twelve 
drugs elicited a 50% increase in synthetic lethality when combined with METTL13 depletion 
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(Table S3); these drugs predominantly inhibit the PI3K-mTOR and MAPK pathways (e.g. 
Omipalisib, Dactolisib, and Trametinib). Relative to control, treatment of pancreatic (T3M4) and 
lung (A459) cancer cells with the dual pan-PI3K/mTOR inhibitor Omipalisib or METTL13 
depletion had modest effects on proliferation, and the combination of Omipalisib treatment with 
METTL13 depletion prevented both cell types from growing (Figure 7C-D). To test whether this 
synergy occurs in an in vivo context, PDX tumors ±METTL13 depletion were treated with 
Omipalisib and tumor growth was monitored (Figure 7E). Notably, PDAC and LAC PDX tumor 
growth stalled or regressed in size by the combination treatment (Figures 7F-G, S7C-D). Based 
on our results, we postulate that eEF1AK55 methylation by METTL13 constitutes a hitherto 
unappreciated mechanism required by neoplasms driven by KRAS pathways to meet their 
increased protein synthesis requirements (Chio et al., 2016; Martineau et al., 2014; Ruggero et 
al., 2004). These data also suggest that the METTL13-eEF1AK55me2 axis may constitute a 
clinically targetable vulnerability of cancers driven by aberrant growth signaling. 
 
DISCUSSION 
 
In a screen of 107 potential KMTs, we identified METTL13 as an active enzyme that 
specifically di-methylates the elongation factor eEF1A at lysine 55. Based on both depletion and 
reconstitution experiments in multiple independent cell lines, including primary pancreatic and 
lung cancer lines, as well as mouse tissue knockouts, we propose that METTL13 is the principal 
enzyme tasked with generating physiologic eEF1AK55me2. Another functionally important 
question we address is whether METTL13 has other lysine substrates besides eEF1AK55, 
particularly in the context of METTL13-associated translation regulation and cancer phenotypes. 
METTL13 does not methylate histones or any of the proteins stably associated with the 40S and 
60S ribosomal subunits or 80S ribosomes. Moreover, eEF1AK55 methylation was the only 
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observed change out of >1000 detected methylation events in cells depleted of METTL13. 
Consistently with the crucial role of eEF1A1/2 proteins in translation elongation and the pivotal 
role of protein synthesis in stimulating cell division (Brooks, 1977), we also observed a role for 
K55 of eEF1A2 in increasing proliferation of pancreatic cancer cells. Together, these findings, in 
combination with the expression patterns of METTL13 and eEF1AK55me2 in cancer, support 
our hypothesis that the biological and pathologic functions of METTL13 reported here are 
mediated through eEF1AK55 methylation. Further support comes from a recently published 
study that independently identified eEF1AK55 to be specifically methylated by METTL13 
(Jakobsson et al., 2018b). 
In the methylation of histones, several KMTs are highly selective enzymes with a single 
physiologic substrate (Carlson and Gozani, 2016); for example, the 7βS KMT hDOT1L 
recognizes a specific topology (the nucleosome) to methylate a single lysine (H3K79). As with 
histones, there are several KMTs – including METTL13 – that are devoted to methylating 
distinct lysines on eEF1A (Hamey and Wilkins, 2018; Jakobsson et al., 2018a). At chromatin, 
methylation dynamics are regulated not only by KMTs, but also by lysine demethylases and 
specific methyl-lysine “reader” domains, which together have a major impact in fine-tuning 
histone functions. We postulate that similar mechanisms are at play in the regulation of 
translation, and that eEF1A demethylases and readers will soon be identified. Future work may 
also uncover crosstalk between eEF1AK55 methylation and other eEF1A modifications in the 
regulation of translation elongation in diverse settings including human disease. Finally, it will 
also be interesting to explore potential roles for K55me2 in regulating non-canonical eEF1A 
functions such as RNA export, AKT signaling, and degradation of newly synthesized 
polypeptides (Abbas et al., 2015; Gandin et al., 2013).  
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Translation is amongst the most energy consuming processes in cells and dysregulation in 
translation mechanisms is a common etiologic agent in neoplastic diseases (Bhat et al., 2015; 
Robichaud et al., 2018; Truitt and Ruggero, 2016). Here we have provided evidence for a model 
in which METTL13-mediated methylation of eEF1A increases translation elongation and 
enhances protein synthesis to promote oncogenesis (see Figure S7E). METTL13 and 
eEF1AK55me2 protein levels are higher in transformed versus non-transformed cells, and higher 
in malignant Ras-driven pancreatic and lung cancer tissue relative to adjacent normal tissue. 
Consistently, increased expression of eEF1A1/2 is frequent in malignancies (Lee and Surh, 
2009). Deletion of METTL13 profoundly inhibited the ability of oncogenic Ras to drive the 
development of pancreatic and lung cancers in vivo and greatly reduced tumor growth in mice of 
PDX models from primary human pancreatic and lung tumors. In contrast, METTL13 appears to 
be dispensable for proliferation of non-transformed cells and normal development of the 
pancreas. In this regard, the paradigm that translational capacity is in excess in normal tissue but 
becomes restrictive for tumorigenesis was established in mice haploinsufficient for eIF4E (Truitt 
et al., 2015). Notably, these mice develop normally, but like METTL13-deleted mice, Ras-driven 
tumorigenesis is attenuated in the LAC mouse model (Truitt et al., 2015); indeed inhibition of 
translation initiation with the eIF4A inhibitor SDS-1-021 (Chu et al., 2016) impacted cancer cells 
with aberrant Ras signaling but not IMR90 cells (Figure S7F-G). Our results raise the possibility 
that METTL13-eEF1AK55me2 enhancement of translation elongation becomes rate-limiting in 
growth signal-driven tumors like PDAC and LAC, which could potentially render these lethal 
cancers vulnerable to METTL13 inhibition. This is consistent with the findings that the eEF2-
dependent modulation of translation elongation rates may play a context-dependent role in 
determining the fate of cancer cells (Faller et al., 2015; Leprivier et al., 2013). 
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  In addition to PDAC and LAC, METTL13 depletion attenuated proliferation in two 
squamous cell lung cancer cell lines (NCI-H2170 and H520) with activated PI3K, suggesting a 
relatively broad oncogenic role for METTL13. In a focused cell-based small molecule screen we 
identified PI3K inhibitors and several other oncogenic growth pathway inhibitors that selectively 
cooperate with METTL13 depletion to prevent pancreatic and lung PDX tumor growth. As 
METTL13 appears to be selectively needed in the transformed cellular state and nonessential in 
normal tissue, a METTL13 inhibitor, in the context of a combination treatment strategy, may 
help overcome the narrow therapeutic index of compounds targeting growth signaling (e.g. 
PI3K) (Infante et al., 2014). In summary, we have identified METTL13 methylation of 
eEF1AK55 as a mechanism to regulate translation elongation and promote tumorigenesis. These 
results identify the METTL13-eEF1AK55me2 axis as a vulnerability of growth signaling-driven 
malignancies and provide a molecular basis for the future development of METTL13 inhibitors 
for the clinic.   
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FIGURE LEGENDS  
 
Figure 1. Identification of METTL13 as a Candidate eEF1A Lysine 55 Methyltransferase. 
(A) Schematic of human eEF1A with the indicated major lysine methylation sites and protein 
domains. Methylated lysine residues are indicated by grey dots. Arrows connect the enzyme 
responsible for methylation with the indicated lysine residue. The “?” indicates that the enzyme 
for generating K55 methylation is unknown.  
(B) eEF1AK55 is primarily di-methylated in human cell lines. Quantitative analysis of 
endogenous eEF1AK55 methylation levels in the indicated cell lines by mass spectrometry.  
(C) Specific recognition of eEF1AK55me2 peptides by the anti-eEF1AK55me2 antibody. Dot 
blot analysis with αeEF1AK55me2 antibody (K55me2) using the indicated biotinylated peptides. 
Blots probed with HRP-conjugated streptavidin (strep-HRP) shown as loading controls.  
(D) Schematic of gene editing-coupled biochemical screening strategy to discover candidate 
KMT/s responsible for eEF1AK55 methylation. See Table S1 for list of the 322 sgRNAs. 
(E) Identification of METTL13 as a putative eEF1AK55 methyltransferase. Western analysis 
with the indicated antibodies of U2OS whole cell lysates expressing CRISPR/Cas9 and three 
independent sgRNAs targeting METTL13 (as in Figure S1F) and the control sgRNA (as in 
Figure S1E). Total eEF1A levels do no change and tubulin is shown as a loading control. 
See also Figure S1, Table S1 
 
Figure 2. In vitro Methylation of eEF1A at Lysine 55 by METTL13.  
(A) In vitro methylation assay with recombinant METT13 and recombinant wild-type GST-
eEF1A1/2 or K55R mutants as indicated. Top panel, 3H-SAM is the methyl donor and 
methylation visualized by autoradiography. Bottom panel, Coomassie stain of proteins in the 
reaction. Asterisk in (A-C, E) indicates METTL13 breakdown product.  
(B) In vitro methylation assay as in (A) with non-radiolabeled SAM. Top panel, Western 
analysis with anti-eEF1AK55me2. Bottom panel, Coomassie stain of proteins in the reaction.  
(C) The N-terminal MT1 domain of METTL13 is necessary for eEF1AK55 methylation. In vitro 
methylation assay on GST-eEF1A1 with recombinant wild-type METTL13 or the indicated 
domain deletion fragments. Top panel, schematic diagram of putative methyltransferase (MT) 
domains of METTL13 and the truncated fragments used in methylation assays. Middle panel, 
autoradiogram of methylation assay. Bottom panel, Coomassie stain of proteins in the reaction. 
(D) Amino acids 1-401 of METTL13 are sufficient for eEF1AK55 methylation. In vitro 
methylation assay on GST-eEF1A1 with wild-type METTL13 or the indicated METTL13 
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truncated proteins. Top panel, autoradiogram of methylation assay. Bottom panel, Coomassie 
stain of proteins in the reaction.  
(E) Identification of METTL13 catalytic mutant. In vitro methylation assay on GST-eEF1A1 
with wild-type METTL13 or METTL13 G58R mutant. Top panel, autoradiogram of methylation 
assay. Bottom panel, Coomassie stain of proteins in the reaction. 
See also Figure S2 
 
Figure 3. The Principal Physiologic Activity of METTL13 is eEF1AK55 Methylation. 
(A) METTL13 is required for eEF1AK55 methylation in multiple human cell lines. Western 
analysis with the indicated antibodies of whole cell extracts (WCEs) from the indicated cell lines 
(see methods) expressing two independent sgRNAs targeting METTL13 or a control sgRNA.  
(B) Reconstitution with wild-type METTL13 but not the inactive mutant restores EF1AK55me2 
in cells. Western analysis with the indicated antibodies of WCEs from wild-type or METTL13-
deficient NCI-H2170 cells complemented with CRISPR-resistant METTL13 (WT or G58R), or 
control as indicated. 
(C) Histones and nucleosomes are not methylated by METTL13. In vitro methylation assay as in 
Figure 2 on recombinant GST-eEF1A1, core histones (H2A, H2B, H3, and H4) or recombinant 
nucleosome (rNuc) with METTL13. eEF1A breakdown products containing K55 are seen below 
full-length with long exposure. Top panel, autoradiogram of methylation assay. Bottom panel, 
Coomassie stain of proteins in the reaction. 
(D) Purified ribosomes are not methylated by METTL13. In vitro methylation assay as in (C) on 
recombinant GST-eEF1A1, 40S and 60S ribosomal subunits, and 80S ribosomes isolated from 
cytoplasmic extracts of T3M4 cells with indicated METTL13 protein.  
(E) Methylation of eEF1AK55 is the only change out of >1000 methylated events detected upon 
METTL13 depletion in cells. Top panel, Western analysis with the indicated antibodies of WCEs 
from control or METTL13-depleted T3M4 cells maintained in SILAC media. Bottom panel, 
SILAC-based quantitative proteomic analysis of methylated peptides in cells ±METTL13. 
Methylated peptides are plotted by their SILAC ratios in two independent experiments in the 
forward (x axis) and reverse (y axis) experiments. Any methylated peptide that is dependent 
upon METTL13 will reside in the top right quadrant. Of the >1000 methylated peptides detected 
in the analysis (see Table S2), only the two eEF1A peptides harboring K55me1 and K55me2 are 
present in the top right quadrant as indicated in red. L/H, light over heavy fraction ratio. 
See also Figure S3, Table S2 
 
Figure 4. METTL13 and eEF1AK55me2 Promote Cancer Cell Proliferation. 
(A) Representative IHC images showing METTL13 and eEF1AK55me2 expression in pancreatic 
cancer lesions (arrowheads) but not in adjacent normal acini (asterisk) in human tissue samples 
(representative of 12 independent samples). Scale bars, 100 µm. The area marked with dotted 
lines is presented at higher magnification in the insets. 
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(B and C) Analysis of correlation of METTL13 (B) and eEF1AK55me2 (C) staining and PDAC 
patient survival assessed by IHC. ***P < 0.001, log-rank test, 72 different samples were stained 
in total for each antibody, a representative staining presented on the right. Scale bars: 100 µm. 
(D) Correlation analysis of METTL13 and eEF1AK55me2 IHC signal (from B-C and S4E-F). 
Spearman correction r = 0.715, P-value < 0.0001, data presented as percent of samples in each 
category (see Methods).  
(E) Upregulation of METTL13 expression and eEF1AK55me2 levels in pancreatic and lung 
cancer cells compared to non-transformed cell lines. Western analysis with the indicated 
antibodies of WCEs from the indicated cell lines. IMR90 are normal human fibroblasts, RPE-1 
are immortalized non-transformed human epithelial cells. Tubulin is shown as a loading control. 
(F and G) METTL13 depletion inhibits cell proliferation in a PDAC cell line but not in non-
transformed cells. Western analysis (top pane) of WCEs and cell proliferation rates (bottom 
panel) of the non-transformed cell line RPE-1 (F) and human PDAC cell line T3M4 (G) 
expressing two independent METTL13 sgRNAs or a control sgRNA. Error bars represent S.D. 
from three independent experiments. **P < 0.01, n.s., not significant, two-tailed unpaired 
Student’s t-test. 
(H) METTL13 catalytic activity is required for METTL13-dependent proliferation of T3M4 
cells.  Western analysis and cell proliferation rates as in (G) of control or METTL13-depleted 
T3M4 cells complemented with CRISPR-resistant METTL13WT, METTL13G58R or control. Error 
bars represent S.D. from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, 
n.s., not significant, two-tailed unpaired Student’s t-test. 
(I) Role for intact K55 on eEF1A2 in promoting T3M4 proliferation. Western analysis and cell 
proliferation rates as in (G) of eEF1A2-depleted T3M4 cells complemented with CRISPR-
resistant eEF1A2WT, eEF1A2K55R or control. Error bars represent S.D. from three independent 
experiments. **P < 0.01, ***P < 0.001, n.s., not significant, two-tailed unpaired Student’s t-test. 
See also Figure S4 
 
Figure 5. METTL13-mediated eEF1AK55 Dimethylation Enhances Protein Synthesis in 
Cells.  
(A) Purification of recombinant eEF1A1 ±K55me2. Top and middle panels, Western analysis 
with the indicated antibodies of eEF1A purified from 293T cells ±catalytically active METTL13 
as indicated. Bottom panel, Coomassie stain of purified eEF1A1.  
(B) K55me2 increases the catalytic efficiency of GTP hydrolysis by eEF1A. The Michaelis-
Menten kinetic parameters of Flag-eEF1A1 ±K55me2 purified from (A) are shown.  
(C) Cytosolic extracts were isolated from control or METTL13-depleted T3M4 cells and 
fractionated on 5-50% sucrose gradients. Absorbance profiles show distribution of 40 and 60S 
ribosomal subunits, 80S monosome and polysomes. OD260nm, optical density at 260 nm. Left 
panel, Western analysis represents WCEs from the indicated cell lines used for the polysome 
profiling. 
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(D and E) SUnSET assays under the indicated conditions reveal reduced protein production in 
METTL13-depleted T3M4 (D) and NCI-H2170 (E) cells. WCEs were isolated and probed the 
indicated antibodies. 
(F) AHA labeling under the indicated conditions shows decrease in protein synthesis upon 
depletion of METTL13 in T3M4 cells. WCE of T3M4 probed with the indicated antibodies. 
(G) METTL13’s catalytic activity is required for enhanced protein synthesis in cells. SUnSET 
assays as in (D) of control (sgControl plus vector control) or METTL13-depleted T3M4 cells 
complemented with CRISPR-resistant METTL13WT, METTL13G58R or control as indicated and 
after recovery from serum starvation. WCEs were isolated and probed the indicated antibodies. 
See also Figure S5 
Figure 6. METTL13 Deletion Represses KRAS-driven Pancreatic and Lung Tumorigenesis 
In Vivo. 
(A) Schematic of the caerulein pancreatitis-induced precancerous (PanINs) lesion formation 
protocol used in Kras;Mettl13 and Kras (control) mice. 
(B) Representative examples of pancreata gross images (representative of 12 independent 
samples). Scale bar, 1 cm. 
(C) Representative haematoxylin and eosin (HE) staining and IHC for MUC5, a marker of 
PanIN lesions, Ki67, a marker of cell proliferation, METTL13 and eEF1AK55me2 
(representative of 12 independent samples). Scale bars, 100 µm. 
(D) Quantification of Ki67-positive proliferating cell and MUC5-positive lesions in caerulein-
treated pancreata from Kras control (n = 12) and Kras;Mettl13 (n = 12). ***P < 0.001, two-
tailed unpaired Student’s t-test. Data are represented as mean ± s.e.m. 
(E) Westerns with the indicated antibodies of pancreatic tissue lysates from Kras;Mettl13 and 
Kras (control) mutant mice (two independent and representative samples are shown for each 
genotype). 
(F) Kaplan-Meier survival curves of Kras;p53 control mice (n = 10, median survival = 54 d) and 
Kras;p53;Mettl13 mutant mice (n = 6, median survival = 86 d). ***P < 0.001, log-rank test for 
significance. 
(G) Representative MRI scan in 7th week to analyze tumor volume in Kras;p53;Mettl13 and 
Kras;p53 mutant mice. Red dotted lines indicate pancreas area; abbreviations used: P=pancreas, 
S=stomach, K=kidney, Sp=spleen. Scale bars, 1cm. 
(H) Tumor/pancreas volume quantification in 7th week of age based on MRI scan (detailed 
procedure in Methods) of Kras;p53;Mettl13 and Kras;p53 mice (n = 4, each genotype) ***P < 
0.001, two-tailed unpaired Student’s t-test. Data are represented as mean ± s.e.m. 
(I) Representative HE and IHC for Ki67 (a maker of proliferation) and Cleaved Caspase 3 
(Cl.Casp 3, a marker of apoptosis) in pancreas tumors at autopsy in Kras;p53;Mettl13 and 
Kras;p53 mutant mice. Scale bars, 100 µm, insets magnification x10. 
(J) Quantification of Ki67-positive proliferating cell and Cleaved Caspase 3 apoptotic cells in 
pancreata at autopsy from Kras;p53 control (n = 6) and Kras;p53;Mettl13 (n = 6) mutant mice. 
***P < 0.001, two-tailed unpaired Student’s t-test. Data are represented as mean ± s.e.m. 
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(K) Representative macroscopic picture of lungs, HE staining and IHC for phospho-Histone H3 
(pH3, a marker of proliferation), METTL13 and eEF1AK55me2 (representative of 8 independent 
samples). Scale bars: yellow 1 cm; black 100 µm. 
(L) Quantification of tumor number, tumor area (burden) and phospho Histone H3-positive 
(pH3+) proliferating cells per lung area in Kras control (n = 8) and Kras;Mettl13 (n = 8). ***P < 
0.001, two-tailed unpaired Student’s t-test. Data are represented as mean ± s.e.m. 
See also Figure S6 
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Figure 7. Depletion of METTL13’s Catalytic Activity Inhibits Growth of Pancreatic and 
Lung Cancer PDX Tumors in vivo and Regression of PDX Tumors by METTL13 Depletion 
and PI3K/mTOR Inhibitors. 
(A) Tumor volume quantification for patient derived PDAC xenografts modified to express 
sgRNA METTL13 or sgRNA control and overexpressing METTL13WT or catalytically deficient 
METTL13G58R in mice (n = 8 mice for each treatment group). ***P < 0.001, two-tailed unpaired 
Student’s t-test. Data are represented as mean ± s.e.m. Westerns with the indicated antibodies of 
PDX biopsies (one representative sample for each condition is shown). 
(B) Tumor volume quantification for patient derived LAC xenografts modified to express 
sgRNA METTL13 or sgRNA control and overexpressing METTL13WT or METTL13G58R in 
mice (n = 8 mice for each treatment group). ***P < 0.001, two-tailed unpaired Student’s t-test. 
Data are represented as mean ± s.e.m. Westerns with the indicated antibodies of PDX biopsies 
(one representative sample for each condition is shown).  
(C) Population growth of T3M4 pancreatic cancer cell line depleted for METTL13 by 
CRISPR/Cas9 sgRNA (sgMETTL13) or control (sgControl). Confluency of cells over 96h 
treated with Omipalisib (1µM) or placebo (vehicle). ***P < 0.001, two-tailed unpaired Student’s 
t-test. Data are represented as mean ± s.e.m (three independent experiments). Westerns of WCE 
with the indicated antibodies are shown.  
(D) Population growth of A549 lung cancer cell line depleted for METTL13 by CRISPR/Cas9 
sgRNA (sgMETTL13) or control (sgControl) as in (C). ***P < 0.001, two-tailed unpaired 
Student’s t-test. Data are represented as mean ± s.e.m (three independent experiments). Westerns 
of WCE with the indicated antibodies are shown.  
(E) Treatment schedule for administration of Omipalisib (GSK2126458, 1 mg kg−1, 
intraperitoneal injection once daily) to immunocompromised mice grafted with PDX pancreatic 
(see F) or lung cancer (see G). Control mice received placebo (vehicle). Treatment started when 
tumors were around 150 mm3. 
(F and G) Tumor volume quantification for patient derived (C) PDAC and (D) LAC xenografts 
modified to express sgRNA METTL13 or sgRNA Control treated with placebo (vehicle) or 
Omipalisib. Plots showing fold change in tumor volume compared to initial tumor volume. ***P 
< 0.001, n.s., not significant, two-tailed unpaired Student’s t-test. Data are represented as mean ± 
s.e.m. 
See also Figure S7, Table S3 
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STAR METHODS 
 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact: Or Gozani (ogozani@stanford.edu).  
 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Mice 
Ptf1a+/Cre, Kras+/LSL-G12D, Trp53loxP/loxP mice have been described before (Hingorani et al., 2003). 
Conditional Mettl13loxP/loxP gene (NCBI Reference Sequence: NM_144877.1) knockout mice 
were generated in this study. Briefly, to engineer the targeting vector, homology arms and exon 
3 (conditional knockout region) was generated by PCR using BAC clone RP23-270A15 and 
RP24-316J6 from the C57BL/6J library as template. The targeting vector includes the self-
excising Neo cassette flanked by Rox sites and exon 3 sequence were flanked by LoxP sites. 
DTA cassette (Diphtheria Toxin A) was used for negative selection. The linearized vector was 
subsequently delivered to ES cells (C57BL/6) via electroporation, followed by drug selection, 
PCR screening, and Southern Blot confirmation. Correctly targeted ES clones were selected for 
blastocyst microinjection, followed by founder mice production. Founders were confirmed as 
germline-transmitted via crossbreeding with wild-type animals. In conjunction with germ line 
transmission of the mutant allele the self-excising Neo cassette was deleted. Mice were in a 
mixed C57BL/6;129/Sv background, and we systematically used littermates as controls in all the 
experiments. Immunocompromised NSG mice (NOD.SCID-IL2Rg-/-) were utilized for 
transplantation studies. All experiments were performed on balanced cohorts of male and 
female mice as our initial data did not indicate significant differences in disease progression or 
response to treatment between females or males. All animals were numbered and experiments 
were conducted in a blinded fashion. After data collection, genotypes were revealed and 
animals assigned to groups for analysis. For treatment experiments mice were randomized. 
None of the mice with the appropriate genotype were excluded from this study or used in any 
other experiments. Mice had not undergone prior treatment or procedures. Husbandry and 
housing conditions: All mice were fed a standard chow diet ad libitum and housed in pathogen-
free facility with standard controlled temperature, humidity, and light-dark cycle (12h) conditions 
with no more than 5 mice per cage under the supervision of veterinarians, in an AALAC-
accredited animal facility at the University of Texas M.D. Anderson Cancer Center. All animal 
procedures were reviewed and approved by the MDACC Institutional Animal Care and Use 
Committee (IACUC 00001636, PI: Mazur).  
 
Cell Lines 
293T (female, embryonic kidney) cells were grown in DMEM medium supplemented with 10% 
fetal calf serum. U2OS (human bone osteosarcoma) cells were cultured in McCoy's 5a medium 
supplemented with 10% fetal bovine serum and 100 U/mL penicillin/streptomycin. Colo-357 
(female, 77 years old, pancreatic cancer), L3.3 (female, 77 years old, pancreatic cancer), 
PaTu8902 (female, 44 years old, pancreatic cancer), and T3M4 (male, age not reported, 
pancreatic cancer) and HT1080 (male, 35 years old, fibrosarcoma) cells were cultured in DMEM 
supplemented with 10% fetal bovine serum, glutamine, and 100 U/mL penicillin/streptomycin. 
NCI-H2170 (male, age not reported, lung cancer) and NCI-H520 (male, age not reported, lung 
cancer) cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum 
and 100 U/mL penicillin/streptomycin. RPE-1 cells (human epithelial cells immortalized with 
hTERT) were from ATCC and cultured in DMEM:F12 medium supplemented with 10% fetal 
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bovine serum, 100 U/mL penicillin/streptomycin, and 0.01mg/mL hygromycin B. IMR-90 (female, 
16 weeks gestation, normal lung fibroblast) were from ATCC and cultured in EMEM 
supplemented with 10% fetal bovine serum and 100 U/mL penicillin/streptomycin. All cells were 
cultured at 37°C in a humidified incubator with 5% CO2. Cell lines were authenticated by short 
tandem repeat profiling and tested negative for mycoplasma (DDC Medical). Serum stimulation 
was performed after serum-starving overnight using regular 10% fetal bovine serum. For 
quantitative proteomics, wild-type and METTL13-depleted T3M4 cells were grown in SILAC 
media containing light or heavy amino acids (13C 15N -L-lysine/13C 15N - L-arginine, see Key 
Resources Table). 
 
Human Tumor Samples 
Surgically resected tumor specimens were obtained from patients with histologically confirmed 
pancreatic cancer and non-small cell lung cancer blinded for age and gender. All surgically 
resected tumors were collected after written patient consent and in accordance with the 
institutional review board-approved protocols of the University of Texas M.D. Anderson Cancer 
Center (LAB07-0854, LAB10-0704). Information on gender and age were not associated with 
tumor samples and hence blinded. 
 
 
METHOD DETAILS  
 
Pancreatic Cancer Mouse Models 
For pancreatic cancer initiation studies acute pancreatitis was induced at 6 to 8 weeks of age in 
Ptf1a+/Cre;Kras+/LSL-G12D (Kras) and Ptf1a+/Cre; Kras+/LSL-G12D; Mettl13loxP/loxP (Kras;Mettl13) mice by 
administration of 8 hourly intraperitoneal (IP) injections of caerulein (100 µg/kg body weight) 
over 2 consecutive days as described previously (Mazur et al., 2014). Pancreatic lesions were 
analyzed 10 d after the last injection. For survival studies, we used Ptf1a+/Cre;Kras+/LSL-
G12D;Trp53loxP/loxP (Kras;p53) and Ptf1a+/Cre;Kras+/LSL-G12D;Trp53loxP/loxP; Mettl13loxP/loxP 
(Kras;p53;Mettl13) mice, which develop aggressive disease. Mice were followed for signs of 
disease progression. At the end of the experiment, tumors were processed for biochemical, 
histological and immunohistochemical analysis. Histopathological analysis was conducted on 
de-identified slides based on the classification consensus. 
 
Lung Adenocarcinoma Mouse Models 
To generate tumors sporadically in the lungs of Kras+/LSL-G12D and Kras+/LSL-G12D; Mettl13loxP/loxP 
mutant mice, we used replication-deficient adenoviruses expressing Cre-recombinase (Ad-Cre) 
to deliver transient Cre recombinase expression to infected cells of the lung, as previously 
described (Mazur et al., 2014). Briefly, 8 to 10-week old mice were anesthetized by continuous 
gaseous infusion of 2% isoflurane for at least 10 min using a veterinary anesthesia system (D19 
Vaporizer, Vetland Medical). Ad-Cre was delivered to the lungs by intratracheal intubation. Prior 
to administration, Ad-Cre was precipitated with calcium phosphate to improve the delivery of 
Cre by increasing the efficiency of viral infection of the lung epithelium. Mice were treated with 
one dose of 5 × 106 PFU of Ad-Cre (Baylor College of Medicine, Viral Vector Production Core). 
Mice were analyzed for tumor formation and progression at 16 weeks after infection. 
 
Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) experiments were performed on Kras;p53 and 
Kras;p53;Mettl13 mutant mice at an age of 7 weeks. Before imaging, mice were anesthetized by 
continuous gaseous infusion of 2% isoflurane for at least 10 min using a veterinary anesthesia 
system (D19 Vaporizer, Vetland Medical). During imaging, the dose was kept at 2% isoflurane, 
animal temperature was maintained and continuously monitored, respiratory and ECG 
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monitoring were performed using an MRI-compatible physiological monitoring system (Small 
Animal Instruments, Inc) and eyes were protected with an eye ointment. MRI was performed 
using the Biospec USR70/30 (Bruker Biospin MRI, Billerica, MA) a small animal experimental 
MR imaging system based on an actively-shielded 7 T magnet with a 30 cm bore and cryo-
refrigeration. The system is equipped with 6 cm inner-diameter gradients that deliver a 
maximum gradient field of 950 mT m−1. A 3.5 cm inner-diameter linear birdcage coil transmits 
and receives the MR signal. For image acquisition, T2-weighted, respiratory gated, multi-slice 
imaging will be performed with respiration held to under 25 breaths per minute to minimize 
motion artefacts in the abdomen. The rapid acquisition with relaxation enhancement (RARE) 
T2-weighted pulse sequence was modified to include an effective Te (time of echo) of 38 ms, 
echo train length 9.5 ms, and number of averages equal to 4 in both the coronal and axial 
planes with a total TR (time repetition) of 2000 ms. A three‐orientation (axial, sagittal, and 
coronal) scout image using a fast, low‐angle single shot sequence was obtained to localize the 
mouse pancreas. Between 18 and 20 coronal and axial slices were acquired per mouse with a 
slice thickness of 0.7 mm and slice spacing of 1 mm to cover the entire pancreas. In plane, pixel 
sizes of 0.156 mm × 0.156 mm with a matrix size of 256 × 192 and field of view (FOV) of 40 mm 
× 30 mm was chosen to minimize in plane partial volume effects, maintain a FOV sufficient to 
cover the abdomen, while also providing sufficient throughput for the experiment. MR images 
were analyzed using an open source Horos processing software. Pancreas tumor burden was 
measured by tracing the outer border of the region of suspected lesions on each slice after 
image intensities were normalized. Analysis was conducted on de-identified images. Tumor 
volume (V) was assessed, using three-dimensional volumetric measurements according to the 
modified Simpson rule. In all contiguous transverse images, the area of tumor (A) in each slice 
was multiplied by the slice profile (0.7 mm slice thickness plus 1 mm intersection gap), and total 
tumor volume was automatically calculated by summation of the adjacent volume according to 
the formula:   
 =  	×		



 
 
where Ts is the thickness of each slice, i is the individual slice number and n is the total number 
of slices. 
 
Histology and Immunohistochemistry 
Tissue specimens were fixed in 4% buffered formalin for 24 hours and stored in 70% ethanol 
until paraffin embedding. 3-µm sections were stained with hematoxylin and eosin (HE) or used 
for immunohistochemical studies. Human tissue sections were collected in accordance with the 
institutional review board-approved protocols of the University of Texas M.D. Anderson Cancer 
Center (LAB05-0854). Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin 
embedded mouse and human tissue sections using a biotin-avidin method as described before 
(Mazur et al., 2014). The following antibodies were used (at the indicated dilutions): cleaved 
caspase 3 (1:200), Ki67 (1:1,000), MUC5AC (1:500), METTL13 (1:100) and eEF1AK55me2 
(1:500). Sections were developed with DAB and counterstained with hematoxylin. Pictures were 
taken using a Leica microscope equipped with the LAX software. Analysis of the tumor area and 
IHC analysis was done using ImageJ software by measuring pixel units. Quantification of 
chromogen intensity was performed by measuring the reciprocal intensity of the chromogen 
stain. Briefly, standard RGB color images acquired from bright field microscopy have a 
maximum intensity of value 250 (represented by white, unstained areas) as measured by the 
standard intensity function in the open source Fiji software (ImageJ). We subtracted the 
intensity of a stained tissue sample from 250, thereby deriving a reciprocal intensity that is 
directly proportional to the amount of chromogen present.  
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Preparation of Pancreatic Epithelial Explants Culture 
Pancreatic epithelial explants from 6-week old wild-type mice were established by modification 
of previously published protocols (Mazur et al., 2014). In brief, the whole pancreas was 
harvested and treated twice with 1.2 mg/ml Collagenase VIII. Following multiple wash steps with 
McCoy’s medium containing soybean trypsin inhibitor (SBTI, 0.2 mg/ml), digested samples were 
filtered through a 100 µm filter, resuspended in culture medium (Waymouth’s MB 752/1 
supplemented with 0.1% BSA, 0.2 mg/ml SBTI; 50 µg/ml bovine pituitary extract, 10 µg/ml 
Insulin, 5 µg/ml transferrin, 6.7 ng/ml selenium in 30% fetal bovine serum) and allowed to 
recover for 1h at 37°C. Thereafter, cells were pell eted and resuspended in culture medium 
supplemented with penicillin G (1000 U/ml), streptomycin (100 µg/ml), amphotericin B, 0.1% 
fetal bovine serum, and an equal volume of rat tail collagen and immediately plated on plates 
pre-coated with 2.5 mg/ml of rat tail collagen type I. In stimulation experiments, recombinant 
mouse EGF was added to a final concentration of 25 ng/ml. For quantification, acinar explants 
were seeded in triplicate. Cell clusters were counted from at least 3 optical fields/well and 
reported as a percentage of acinar clusters and duct-like spheres. The quantification was 
performed in two independent experiments; the number of mice is reported in the main text. 
 
Meta-analysis of Gene Expression 
Meta-analysis of public PDAC and NSCLC data sets. We downloaded raw data for gene 
expression studies (7 pancreatic cancer, 6 NSCLC) from the NCBI GEO and EBI ArrayExpress. 
After re-annotating the probes, each data set was normalized separately using gcRMA. We 
applied two meta-analysis approaches to the normalized data. Briefly, the first approach 
combines effect sizes from each data set into a meta-effect size to estimate the amount of 
change in expression across all data sets. For each gene in each data set, an effect size was 
computed using Hedges’ adjusted g. If multiple probes mapped to a gene, the effect size for 
each gene was summarized using the fixed effect inverse-variance model. We combined study-
specific effect sizes to obtain the pooled effect size and its standard error using the random 
effects inverse-variance technique. We computed z-statistics as a ratio of the pooled effect size 
to its standard error for each gene and compared the result to a standard normal distribution to 
obtain a nominal P-value. P-values were corrected for multiple hypotheses testing using false 
discovery rate (FDR). We used a second non-parametric meta-analysis that combines P-values 
from individual experiments to identify genes with a large effect size in all data sets. Briefly, we 
calculated a t-statistic for each gene in each study. After computing one-tail P-values for each 
gene, they were corrected for multiple hypotheses using FDR. Next, we used Fisher’s sum of 
logs method, which sums the logarithm of corrected P-values across all data sets for each gene 
and compares the sum against a chi-square distribution with 2k degrees of freedom, where k is 
the number of data sets used in the analysis. 
 
Patient-derived Cancer Xenografts  
Surgically resected tumor specimens were obtained from patients with histologically confirmed 
pancreatic cancer and non-small cell lung cancer blinded for age and gender. All surgically 
resected tumors were collected after written patient consent and in accordance with the 
institutional review board-approved protocols of the University of Texas M.D. Anderson Cancer 
Center (LAB07-0854, LAB10-0704). Patient-derived xenograft tumors were generated by 
transplanting small tumor fragments isolated directly from surgical specimens subcutaneously 
into mice. In each case we first propagated the sample in NSG mice. For reconstitution assays, 
collected PDX tumors were minced using a razor blade and digested in collagenase digestion 
buffer at 37°C for 1 hour. Cells were passed throug h 100 µm and 40 µm cell strainers and 
centrifuged for 1200 rpm for 8 min. Cells were incubated in RBC lysis buffer for 2 min and then 
resuspended in 6 mL of media and spun through 0.5mL of serum layered on the bottom of the 
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tube to remove cellular debris. Contaminating human or mouse hematopoietic and endothelial 
cells (CD45, Ter119, CD31) are depleted using biotin conjugated anti-mouse CD45, CD31 and 
Ter119 antibodies and separated on a MACS LS column using anti biotin microbeads. The 
isolated cells are transiently cultured on several matrigel coated plates and infected with 
lentivirus carrying sgRNA Mettl13 (shMettl13) and cDNA of METTL13 WT, METTL13 catalytic 
dead mutant and briefly selected using appropriate antibiotics. Then cells were collected, mixed 
with matrigel (1:1) and transplanted to the flanks of NSG mice. When tumors became palpable, 
they were calipered every 3 days to monitor growth kinetics.  Tumor volume was calculated 
using the formula: Volume = (width)2 x length / 2 where length represents the largest tumor 
diameter and width represents the perpendicular tumor diameter. 
 
Transfection and Viral Transduction  
Transient expression was performed using TransIT-293 (Mirus Bio) following the manufacturer’s 
protocol. For CRISPR/Cas9 knockouts, virus particles were produced by co-transfection of 293T 
cells with the lentiCRISPR v2 /hygro construct expressing indicated sgRNAs, pCMV-VSV-G and 
pCMV-dR8.2 dvpr in a ratio of 5:2:3 by mass. 48 hours after transfection, target cells were 
transduced with 0.45 µm filtered viral supernatant and 4 µg/mL polybrene. Cells were selected 
24h after media replacement with 12.5 µg/mL puromycin for RPE-1 or 250 µg/mL hygromycin B 
for other cell lines. For METTL13 reconstitution, cells were transduced with retroviral pBABE or 
pWZL constructs using pUMVC and pCMV-VSV-G in a ratio of 2:1:1 by mass. The subsequent 
selection was carried out with 800 µg/mL G-418 for NCI-H2170, 2 mg/mL G-418 for T3M4, or 10 
µg/mL blasticidin for 293T cells. For eEF1A2 reconstitution, T3M4 cells were transduced with 
pLenti6.2 plasmid, pCMV-dR8.2 dvpr and pCMV-VSV-G in a ratio of 5:3:2 by mass and selected 
with 20 µg/mL blasticidin. 
 
Plasmids  
Protein sequences were METTL13 (accession no. NP_057019.3), eEF1A1 (accession no. NP_ 
001393.1), and eEF1A2 (accession no. NP_001949.1). Bacterial expression plasmids were 
created using pGEX-6P-1. Transient mammalian expression was conducted using 
pcDNA3.1(+). lentiCRISPRv2 was used for CRISPR/Cas9 knockouts in RPE-1 cells, while 
lentiCRISPRv2 hygro were used in all other cell lines. For stable expression in mammalian cells, 
METTL13 was cloned into pBABE-neo and pWZL Blast GFP. eEF1A2 was originally cloned into 
pENTR3C and then recombined into pLenti6.2 V5-DEST. The inserts were amplified by PCR 
using specific clones from the human ORFeome library as templates. Single point mutations of 
METTL13 and eEF1A2 were generated by site-directed mutagenesis.  
 
CRISPR/Cas9 Knockout Library Screen 
107 known and candidate lysine methyltransferases (KMTs) were identified based on literatrure 
analyses (e.g. (Clarke, 2013)). The top three sgRNAs targeting each putative KMT were taken 
from a previously published genome-wide human sgRNA library (Morgens et al., 2017) (Table 
S1). The control sgRNA, which shows no effect on growth in multiple cell lines, was designed to 
be at least 2 bases mismatched to anything in the human genome. A total of 322 KMT sgRNAs 
were cloned into the lentiCRISPR v2 vector. Lentivirus particles were produced as described 
above. U2OS cells in 6-well plates were infected with virus in 4 µg/mL polybrene for 2 days, 
then expanded into 10 cm plates for 3 days in puromycin at 2 µg/mL. Lysate from each plate 
was collected in 1 mL RIPA buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 1% Triton, 0.1% SDS) supplemented with protease inhibitor cocktail. For Western 
analysis, 40 µL of cell lysates were mixed with 10 µL of 5× SDS loading buffer and boiled for 5 
min. 20 µL was resolved by SDS-PAGE, transferred to a PVDF membrane, and probed with the 
anti-eEF1AK55me2 antibody for screening. Tubulin was used as a loading control.  
 
 36
Immunoblot Analysis and Immunoprecipitation 
For Western blot analysis, cells were lysed in RIPA buffer with 1 mM PMSF and protease 
inhibitor cocktail. Protein concentration was determined using the Pierce Coomassie Plus 
Assay. Protein samples were resolved by SDS-PAGE and transferred to a PVDF membrane 
(0.45 µm). Dot blot analysis was performed by directly loading 1 µL of the indicated amounts of 
biotinylated peptides onto a PVDF membrane (0.2 µm). The following antibodies were used (at 
the indicated dilutions): eEF1AK55me1 (1:3,000), eEF1AK55me2 (1:10,000), eEF1AK55me3 
(1:5,000), eEF1A (1:5,000), beta-tubulin (1:5,000), puromycin (1:2,000), METTL13 (1:2,000), 
peroxidase-conjugated streptavidin (1:10,000), eIF3A (1:5,000), RPS6 (1:2,000), RPL6 
(1:3,000), eEF1A2 (1:2,000). All secondary antibodies were used at 1:10,000 dilution. Protein 
bands were visualized using Amersham ECL or Amersham ECL Prime Western Blotting 
Detection Reagent.  
 
For immunoprecipitation of endogenous eEF1A, equal amounts of whole cell extracts (WCEs) 
were incubated with anti-eEF1A at 4°C for overnight  and then with protein G magnetic beads at 
4°C for 2 hours. The beads were washed with cell ly sis buffer at 4°C three times, boiled in 
Laemmli buffer, and then frozen until processed for MS analysis as described below.   
 
Expression and Purification of Recombinant Proteins 
GST fusion proteins were expressed in BL21 Escherichia coli by overnight culture at 20°C in LB 
medium (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) supplemented with 0.1 mM IPTG 
(isopropyl 1-thio- β-D-galactopyranoside, Sigma), purified using Glutathione Sepharose 4B (GE 
Healthcare) and eluted in 10 mM reduced glutathione (Sigma). Protein concentrations were 
measured using Pierce Coomassie Plus Assay. DTT was added to the protein solution at a final 
concentration of 20 mM. Recombinant human core histones were expressed and purified by 
ion-exchange chromatography. The histones were combined in equimolar ratio under 
denaturing conditions and dialyzed against high salt buffer to assemble octamers. Octamers 
were purified by gel filtration chromatography. Nucleosomes were subsequently assembled with 
the optimized 601 DNA sequence that was amplified with a 5’ biotinylated primer. 
 
For purification of Flag-tagged eEF1A1, eEF1A1 bearing a C-terminal Flag tag was expressed 
by transient transfection in wild-type or METLL13-depleted 293T cells that were reconstituted 
with METTL13WT or METTL13G58R, respectively. After 48h transfection, eEF1A was isolated from 
whole cell extracts using anti-Flag M2 affinity gel (Sigma) according to the instructions of the 
manufacturer and eluted with 3×Flag peptides (Sigma). The resulting purified eEF1A1 was 
immediately used for enzymatic reactions.  
 
Structural Modeling of METTL13 (1-400) 
Structural modeling of the first 400 residues of METTL13 (METTL13 1-400) was performed 
using the I-TASSER software package. Based on the amino acid sequence of METTL131-400, 
the program identified structural templates from Protein Data Bank (https://www.rcsb.org/), 
which were then subject to template-based fragment assembly simulations to generate the 
structural model. The relative orientation of the two subdomains of METTL131-400, MTase and 
SBD, was manually arranged in a similar manner as that of the corresponding domains of PrmA 
(Demirci et al., 2007). 
 
Polysome Profiling 
Wild-type or METTL13-depleted T3M4 cells were seeded into six 15-cm Petri dishes (~10 × 106 
cells per dish) 24 hours prior to serum starvation for 16h followed by replacement with fresh 
medium for 2h. Cells were treated with 100 µg/mL cycloheximide and incubated for 2 min at 
37°C. Cells were washed and scraped in cold PBS con taining 100 µg/mL cycloheximide, 
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pelleted and lysed in lysis buffer (5 mM Tris pH7.4, 2.5 mM MgCl2, 1.5 mM KCl, 100 µg/mL 
cycloheximide, 2 µM DTT, 0.5% Triton, 0.5% Na-DOC, 100 U/mL SUPERase In RNase inhibitor 
and protease inhibitors). Lysates were cleared for 10 min at 14,000 rpm at 4°C. RNA contents 
were determined by Nanodrop and 500 µg of RNA were loaded on 10% to 50% sucrose 
gradients made in 15 mM Tris pH7.4, 15 mM MgCl2, 150 mM NaCl and prepared using a 
BioComp Gradient Station. Gradients were spun for 2 hours in a TH-641 rotor (Sorvall) at 
40,000 rpm and 4°C. Gradients were analyzed (260 nm ) and fractions collected with a BioComp 
Gradient Station. 
 
Methylation and GTPase Assays 
In vitro methylation assays were performed similar to as descrbied in (Mazur et al., 2014) by 
combining 3 µg of recombinant proteins or 1 µg of peptides and equal amounts of recombinant 
enzymes in a methyltransferase buffer (50 mM Tris pH 8.0, 20 mM KCl, 5 mM MgCl2, and 10% 
glycerol) supplemented with 1 mM S-adenosyl-methionine (SAM, New England Biolabs) or 
deuterated AdoMet (C/D/N Isotopes) or 2 µCi of tritiated AdoMet (American Radiolabeled 
Chemicals). The reaction mixtures were incubated overnight at 30°C. Reactions were resolved 
by SDS-PAGE, followed by autoradiography, Coomassie stain or mass spectrometry analysis. 
 
For in vitro methylation assay on ribosomes, 40S and 60S ribosomal subunits and 80S 
ribosomes were isolated from cytoplasmic extract of T3M4 cells as described in Polysome 
Profiling. The eluting fractions were dialyzed twice in 2 L of 100 mM Tris, pH 8.0 (MCWO 3500) 
and then concentrated (MWCO 3000) by centrifugation at 14,000 x g. Methylation reactions 
were carried out in the methyltransferase buffer containing 3 µg of recombinant METTL13 
(amino acids 1-498), 17.5 µL of concentrated ribosomes, and 1 mM S-adenosyl-methionine or 2 
µCi of tritiated AdoMet at 30°C for overnight. The reactions were resolved by SDS-PAGE, 
followed by autoradiography, Coomassie stain or Western blot analysis. 
 
GTPase assays were performed in triplicate using ATPase/GTPase Activity Assay Kit (Sigma) 
following the manufacturer’s protocol. Briefly, 3 µg of Flag-tagged eEF1A1K55me0/2 purified 
from 293T cells (as described above) were incubated with increasing amounts of GTP in 30 µL 
of the reaction buffer provided by the kit at 37°C for 3 hours. The reactions were terminated by 
adding 200 µL of the kit reagent and incubating for an additional 30 min at room temperature. 
For GTPase activation by aminoacyl-tRNA (aa-tRNA), the GTPase assays were performed 
using 3 µg of Flag-tagged eEF1A1K55me0/2, 500 µM GTP, 100 ng/µL total aa-tRNAs and 25-
30 units RNasin ribonuclease inhibitors (Promega) in 30 µL of the reaction buffer. Isolation of 
total aa-tRNAs from 293T cells was performed at 4°C  using phenol/chloroform extraction under 
acidic conditions. Formation of hydrolyzed free phosphate was measured at a wavelength of 
620 nm, and absorbance was compared with a standard curve. The readings of background 
blank and negative control reactions were subtracted from the sample readings. The kinetic 
parameters were evaluated by fitting the data to the Michaelis-Menten equation in Origin Pro 8. 
 
Mass Spectrometry (MS) of eEF1AK55 Methylation 
Recombinant and immunoprecipitated eEF1A were separated by SDS-PAGE and stained using 
InstantBlue Protein Stain (Expedeon). Bands were cut and destained in 50% acetonitrile (ACN), 
50% ammonium bicarbonate (NH4HCO3, 50mM) for 10 min twice. Gel pieces were incubated in 
50 mM NH4HCO3 containing 10 mM DTT at 60°C for 30 min, followed by treatment with 25 mM 
iodoacetamide in 50 mM NH4HCO3 at room temperature for 45 min. In-gel digestion was 
performed using 100 ng/µL Glu-C in 50 mM phosphate buffer (pH 7.8) at 37°C or 10 ng/µL 
trypsin in 50 mM NH4HCO3 at room temperature for overnight. Two consecutive peptide 
extractions were processed with 5% formic acid, 49% water, and 50% ACN. The resulting 
peptides were dried by speedvac, desalted using C18 StageTips (Thermo Fisher Scientific), and 
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analyzed on an Orbitrap Elite mass spectrometer. Methylation states of eEF1AK55 were 
manually inspected. Selected ion chromatograms for peptides spanning eEF1AK55 were 
extracted using Xcalibur Qual Browser (Thermo). The settings were as follows:  
Peptide 49-61, m/z 501.255 (me0), 505.927 (me1), 510.599 (me2)  and 515.271 (me3), 10 
p.p.m 
Peptide 49-61 (deuterated K55me), m/z 501.255 (me0), 506.933 (me1), 512.6115 (me2) and 
518.290 (me3), 10 p.p.m 
Peptide 52-62, m/z 664.356 (me1), 671.364 (me2) and 678.372 (me3), 10 p.p.m 
Peptide 52-62 (deuterated K55me), m/z 665.865 (me1), 674.382 (me2) and 682.900 (me3), 10 
p.p.m 
 
Proteome-wide Labeling and Analysis of METTL13 Substrates 
Wild-type and METTL13-depleted T3M4 cells were grown in SILAC media containing either 
normal amino acids (‘light’) or modified amino acids (‘heavy”) for two weeks and lysed in RIPA 
buffer with 1 mM PMSF and protease inhibitor cocktail. A 2-way experiment was performed – 
the ‘forward’ condition combining light WCE + METTL13 with heavy WCE - METTL13 and the 
‘reverse’ condition combining heavy WCE + METTL13 with light WCE - METTL13 at a ratio of 
1:1 by mass. 10 µg of the lysates of each pair were resolved by SDS-PAGE and stained using a 
SilverQuest Silver Staining Kit. Gel pieces were treated with DTT and iodoacetamide as 
described above. In-gel digestion was performed using 25 ng/µL trypsin followed by purification 
using C18 stage tips. To best extract the methylated peptides from the entire proteome, the 
resulting digestion products were analyzed on an Orbitrap Elite mass spectrometer and an 
Orbitrap Fusion mass spectrometer (Thermo Scientific). Data obtained from the two instruments 
were combined and processed using MaxQuant version 1.3.0.5 (Cox and Mann, 2008) and 
allowing as variable modifications – methionine oxidation; mono- and di-methylation of arginine; 
and mono-, di- and tri-methylation of lysine. 
 
Cell Assays 
For cell proliferation assays, cells were seeded at 2 × 105 cells/mL in triplicate in 6-well plates. 
Cell counts were acquired by Countess II FL Automated Cell Counter (Thermo Fisher Scientific) 
at indicated days for 8-10 days. After each counting, the cells were maintained at a density 
between 2-4 × 105 cells/mL. Trypan blue was used to stain non-viable cells. Cell numbers were 
expressed relative to 1 × 105 cells/mL. 
 
Bromodeoxyuridine (BrdU) incorporation assay were conducted fusing Cell Proliferation ELISA 
BrdU Kit. Cells were seeded in 96-well plates (1,000 cells/well for HT1080, PaTu8902; 2,000 
cells/well for T3M4 and colo-357; and 4000 cells for IMR90)  and treated with drug 
concentrations as indicated in the text or with a vehicle for 72h. Absorbance at 370 nm 
(corrected for absorbance at the reference wavelength of 492 nm) was measured using a 
microplate reader (Benchmark Plus microplate reader; Bio-Rad) according to a manufacturer’s 
instructions. Tests were performed in two biological replicates, each carried out in a triplicate. 
BrdU incorporation is expressed as a fraction of vehicle (DMSO) treated control. For viable cell 
counting, 1 × 105 HT1080, PaTu8902, T3M4 and colo-357 cells  and 2 × 105  IMR90 cells were 
seeded in 6-well plates and treated with drug concentrations as indicated in the text or with a 
vehicle for 72h. Non-viable cells were excluded using Trypan blue staining. Tests were 
performed in two biological replicates, each carried out in a triplicate. Viable cell count is 
expressed as a fraction of vehicle (DMSO) treated control. Proliferation curves were generated 
and fitted using GraphPad [using log(inhibitor) vs response – Variable slope (four parameters)]. 
 
Translation Assays 
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For SUnSET assays (Schmidt et al., 2009), wild-type or METTL13-depleted T3M4 and NCI-
H2170 cells were seeded at 2-4 × 105 cells/mL in 6-well plates 24 hours prior to serum 
starvation. For serum stimulation, cells were maintained in regular media containing 10% fetal 
bovine serum for an optimized period (2 hours for T3M4 and 1 h for NCI-H2170). Puromycin 
pulses were performed by incubating the cells with 10 µg/mL puromycin for 15 min at 37°C. 
Cells were then washed with cold PBS and lysed in RIPA buffer supplemented with 1 mM 
PMSF and protease inhibitor mixture. 5-10 µg of the whole cell lysate were assayed by Western 
blot analysis using the anti-puromycin antibody.  
 
For labeling newly synthesized proteins, T3M4 cells were maintained in DMEM free of cysteine 
and methionine for 1h, then grown in DMEM containing 100 µg/mL methionine or AHA (l-
azidohomoalanine) for 2 hours. T3M4 cells under serum starvation were cultured in DMEM free 
of cysteine and methionine for 1h, then grown for 2h in DMEM containing 10% fetal bovine 
serum and 100 µg/mL methionine or AHA. Cells were then harvested, washed with PBS on ice 
and lysed in RIPA buffer. Click reactions were performed using Click Chemistry Reaction Buffer 
Kit (Click Chemistry Tools) following the manufacturer’s protocol. Briefly, 50-100 µg of whole cell 
lysates were incubated with 40 µM Biotin-PEG4-Alkyne for 30 min. The proteins were extracted 
with methanol and chloroform and 1-5 µg were assayed by Western blot analysis using 
streptavidin-conjugated horseradish peroxidase. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
Please refer to the Figure Legends or the Experimental Details for description of sample size (n) 
and statistical details. All values for n are for individual mice or individual sample. Sample sizes 
were chosen based on previous experience with given experiments. Cell culture assays have 
been performed in triplicates and in two independent experiments, unless stated otherwise. 
Data are expressed as mean ± SEM. Differences were analyzed by Spearman's rank 
correlation, log-rank, two-tailed Student’s t test, Mann-Whitney U test, one-way ANOVA (using 
Bonferroni post test), one-sample t test or c2-test using Prism 7 (GraphPad), P-values ≤ 0.05 
were considered significant. 
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Supplementary Figure Legends  
 
Figure S1. Identification of METTL13 as a Candidate eEF1A Lysine 55 Methyltransferase. 
Related to Figure 1  
(A) eEF1AK55 dimethylation is the predominant species in multiple human cell lines. Selected 
ion chromatograms for non-, mono-, di- and trimethyl eEF1AK55 peptides from GluC digestion 
of endogenous eEF1A immunoprecipitated from the indicated whole cell lysates (WCEs). HPLC 
elution profiles show a 10-ppm mass window around expected peptide masses (peptide sequence 
MGKGSFKYAWVLD, K55 is underlined; m/z are 501.255, 505.927, 510.599 and 515.271). 
Red arrows indicate elution peaks of non-, mono- and dimethylated eEF1AK55 peptides in the 
profiles. 
(B) Representative tandem mass spectra identifying mono- (top) and di- (bottom) methylation of 
endogenous eEF1AK55 immunoprecipitated from WCEs as shown in (A) and followed by 
trypsin digestion. m/z for b and y ions observed in spectra were indicated in blue and red, 
respectively.  
(C) Specific recognition of eEF1AK55me by the anti-eEF1AK55me antibodies. Dot blot 
analysis with state-specific eEF1AK55me1-3 antibodies using the indicated biotinylated 
peptides. Blots probed with HRP-conjugated streptavidin (strep-HRP) as loading controls. 
(D) Specificity of the anti-eEF1AK55me2 antibody in dot blot assays using biotinylated 
eEF1AK55me2 peptides and 19 different peptides from the indicated proteins that harbor a 
dimethyl lysine. Blots probed with strep-HRP as loading controls. 
(E) Control small guide RNA (sgRNA) for CRISPR-based screen (Figure 1D). Western analysis 
with the indicated antibodies of WCEs from U2OS cells expressing the control sgRNA from the 
322 sgRNA KMT library and seven randomly selected sgRNAs targeting the potential KMTs in 
the human genome. None of these sgRNAs reduced eEF1AK55me2 levels. 
(F) Identification of METTL13 as a candidate eEF1AK55 di-methyltransferase. Western 
analyses with eEF1AK55me2 and tubulin antibodies of the 322 individual U2OS WCEs. Each 
cell line expresses CRISPR/Cas9 and one of the 322 sgRNAs. There are three independent 
sgRNAs targeting 107 known and candidate KMTs in the human genome. For each indicated 
KMT, eEF1AK55me2 and tubulin protein levels are shown in top and bottom panels, 
respectively and the data is organized alphabetically. 
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Figure S2. METTL13 Methylates eEF1AK55 In Vitro, Related to Figure 2  
(A) METTL13 methylates eEF1A1/2 at K55 in vitro. Selected ion chromatograms for non-, 
mono-, di- and tri-methyl eEF1A1/2-K55 peptides from GluC digestion after in vitro methylation 
with recombinant METTL13 using deuterated SAM as a methyl donor. HPLC elution profiles 
show a 10-ppm mass window around expected peptide masses (peptide sequence 
MGKGSFKYAWVLD, K55 is underlined; m/z are 501.255, 506.933, 512.6115 and 518.290). 
Red arrows indicate elution peaks of non-, mono- and dimethylated eEF1AK55 peptides in the 
profiles. 
(B) Representative tandem mass spectra identifying in vitro mono- (top) and di- (bottom) 
methylation of eEF1AK55 by recombinant METTL13 using deuterated SAM and digested with 
trypsin. m/z for b and y ions observed in spectra were indicated in blue and red, respectively.  
(C) Structural model of METTL131-400, with the MTase domain colored in light pink and the 
SBD domain colored in light blue. The co-factor byproduct S-Adenosyl-L-homocysteine (SAH) 
bound to the MTase domain is shown in sphere representation. The MTase and SBD domains are 
juxtaposed in a random orientation, with the linker sequence depicted as a dark dashed line. The 
SAH-interacting residues are shown in stick representation in the expanded view. The putative 
hydrogen bonds are shown as red dashed lines. 
(D) Identification of point mutations that abrogate METTL13 enzymatic activity. In vitro 
methylation assay on recombinant GST-eEF1A1 with recombinant wild-type METTL13 or the 
indicated METTL13 single point mutations. Top panel, schematic diagram showing two putative 
methyltransferase (MT) domains of METTL13 and mutated residues in the MT1 domain. 
Underlined are signature motifs conserved in METTL13 with other 7βS members with known 
lysine methylation activity. Middle panel, autoradiogram of methylation assay. Bottom panel, 
Coomassie stain of proteins in the reaction. Asterisk indicates METTL13 breakdown product. 
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Figure S3. METTL13 Specifically Methylates eEF1AK55 In Cells, Related to Figure 3  
(A) METTL13 is required for dimethylation of eEF1AK55 in human cell lines. Mass 
spectrometry-based quantification of eEF1AK55 methylation levels in the indicated cell lines 
expressing two independent sgRNAs targeting METTL13 and compared to the levels of sgRNA 
control cells. 
(B) Western analysis with the indicated antibodies of in vitro methylation reactions on 
recombinant GST-eEF1A1, 40S, 60S and 80S ribosomes purified from T3M4 cells with 
recombinant METTL13WT or METTL13G58R. Input represents cytoplasmic extracts from T3M4 
cells used for the isolation of 40S, 60S and 80S. Importantly, no eEF1A signal was detected in 
purified 40S, 60S and 80S fractions. 
(C) Mass spectrometry analysis reveals no METTL13 methylation activity on unmodified 
eEF1AK55 peptide. Selected ion chromatograms for non-, mono-, di- and tri-methyl eEF1AK55 
peptides after in vitro methylation on synthesized unmodified eEF1AK55 peptides (aa 45-65) 
with recombinant METTL13. HPLC elution profiles show a 10-ppm mass window around 
expected peptide masses (peptide sequence EAAEMGKGSFKYAWVLDKLKA, K55 is 
underlined; m/z are 635.590, 639.094, 642.598 and 646.102). Red arrows indicate elution peaks 
of non-methylated eEF1AK55 peptide in the profiles. 
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Figure S4. METTL13 and eEF1AK55me2 are Highly Expressed in Pancreatic and Lung 
Cancers and Promote Cancer Cell Proliferation, Related to Figure 4  
(A) Summary of METTL13 expression levels in six publicly available expression data sets of 
PDAC (n=294 tumors and n=141 normal tissue independent samples). Detailed statistical 
description in the Methods section. 
(B) Correlation of METTL13 mRNA expression levels and overall pancreatic cancer survival. 
Hazard ratio with 95% confidence intervals and log rank P-value are calculated. Data from GEO, 
EGA and TCGA. 
(C) Differential epithelial expression levels of METTL13 and eEF1AK55me2 in human PDAC 
samples as assessed by immunohistochemistry (72 different samples were stained in total, the 
representative staining presented). Scale bars: 100 µm. 
(D) Summary of METTL13 expression levels in six publicly available expression data sets of 
LAC (n=319 tumors and n=147 normal tissue independent samples). Detailed statistical 
description in the Methods section. 
(E) Analysis of correlation of eEF1AK55me2 staining and LAC patient survival assessed by 
immunohistochemistry. ***P < 0.001, log-rank test, 96 different samples were stained in total, 
the representative staining presented. Scale bars: 100 µm. 
(F) Differential epithelial expression levels of METTL13 and eEF1AK55me2 in human LAC 
samples as assessed by immunohistochemistry (96 different samples were stained in total, the 
representative staining presented). Scale bars: 100 µm. 
(G) Cell proliferation rates of human lung cancer cell lines (NCI-H2170 and NCI-H520), human 
osteosarcoma cell line (U2OS), human fibrosarcoma cell line (HT1080) and human pancreatic 
cancer cell lines (PaTu8902 and colo357) expressing CRISPR/Cas9 and two independent 
METTL13 sgRNAs or a control sgRNA. Top panel, Westerns with indicated antibodies of 
WCEs from wild-type or METTL13 deficient cell lines as indicated. Error bars represent S.D. 
from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed unpaired 
Student’s t-test.  
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Figure S5. Methylation Regulates eEF1A GTPase activity and mRNA Translation in Cells, 
Related to Figure 5  
(A) Coomassie stain of purified Flag tagged eEF1A1K55me2 and eEF1A1K44me0 protein.  
(B) In vitro GTP hydrolysis by dimethylated or unmethylated Flag-eEF1A1. Flag-eEF1A1 ± 
K55me2 purified from (A) was incubated with increasing amounts of GTP at 37 °C for 3h. Error 
bars represent S.D. from three independent reactions. Kinetic parameters were obtained by fitting 
the Michaelis-Menten equation to the plot of velocity of phosphate formation against GTP 
concentration.  
(C) The effect of K55 dimethylation on the GTPase activity of Flag-eEF1A1 is independent of 
aminoacyl-tRNAs (aa-tRNAs). Flag-eEF1A1 ± K55me2 purified as in (A) was incubated with 
500 µM GTP in reaction buffer at 37 °C for 3h in the absence or presence of aa-tRNAs. The y 
axis shows velocity of phosphate formation. Error bars represent S.D. from three independent 
reactions. 
(D) Cytosolic extracts were isolated from control or METTL13-depleted T3M4 cells (replicate of 
Figure 5C) and fractionated on 5-50% sucrose gradients. Absorbance profiles show distribution 
of 40 and 60S ribosomal subunits, 80S monosome and polysomes. OD260nm, optical density at 
260 nm. Left panel, Western analysis represents WCEs from the indicated cell lines used for the 
polysome profiling. 
(E) METTL13 depletion does not impact protein synthesis in non-transformed RPE-1 cells. 
SUnSET assays as in Figure 5D show no difference in protein production in RPE-1 cells with or 
without METTL13. After being pulsed with 10 µg/mL puromycin for 15 min at the indicated 
conditions, WCEs were isolated and probed with the indicated antibodies. 
(F) Requirement for eEF1AK55 for serum-stimulated protein synthesis in cells. SUnSET assays 
after recovery from serum starvation as in Figure 5D with control (sgControl plus vector control) 
or eEF1A-depleted T3M4 cells complemented with CRISPR-resistant eEF1A2WT, eEF1A2K55R 
or control as indicated. WCEs were isolated and probed with the indicated antibodies. 
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Figure S6. METTL13 Deletion Represses KRAS-driven Pancreatic and Lung 
Tumorigenesis In Vivo, Related to Figure 6 
(A) Schematic of the Mettl13 conditional allele. In the presence of Cre recombinase, exon 3 is 
deleted to disrupt Mettl13 expression.  
(B) Deletion of Mettl13 exon 3 of the conditional allele (Figure S6A) determined by PCR.  
(C) METTL13 depletion inhibits ADM. Wild-type (WT, Ptf1aCre/+) acinar clusters (asterisk) 
undergo ADM and form ducts (arrowhead) ex vivo, whereas Ptf1aCre/+;Mettl13 mutant (Mettl13) 
acini explants inefficiently form ducts.  
(D) Quantification of acinar and ductal clusters from Figure S6C. ***P < 0.001, n.s. not 
significant, two-tailed unpaired Student’s t-test, four independent biological replicas with three 
technical replicas each. Data are represented as mean ± s.e.m. 
(E) Mettl13 expression by quantitative PCR with reverse transcription (qRT–PCR) analysis at 
the indicated times from control- and EGF-induced ADM ex vivo samples, four independent 
biological replicas as in Figure S6C. 
(F) Immunohistochemical analysis of tumors that emerged in Kras;Mettl13 LAC model reveals 
that tumors retained METTL13 expression suggesting incomplete bi-allelic Cre recombination in 
these clonal growths. Representative staining presented. Scale bars: 1000 µm, insets 
magnification x10. 
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Figure S7.  Depletion of METTL13’s Catalytic Activity Inhibits Growth of Pancreatic and 
Lung Cancer PDX Tumors in vivo and Regression of PDX Tumors by the Combination of 
METTL13 Depletion and Treatment with PI3K/mTOR Inhibitors, Related to Figure 7 
(A) Tumor volume quantification for patient derived PDAC xenografts modified to express 
sgRNA METTL13 or sgRNA control and overexpressing wildtype METTL13WT or catalytically 
deficient METTL13G58R in mice (n = 8 mice for each treatment group). ***P < 0.001, two-tailed 
unpaired Student’s t-test. Data are represented as mean ± s.e.m. Immunoblots with the indicated 
antibodies of the PDX biopsies (one representative sample for each condition is shown). 
(B) Tumor volume quantification for patient derived LAC xenografts modified to express 
sgRNA METTL13 or sgRNA control and overexpressing wildtype METTL13WT or catalytically 
deficient METTL13G58R in mice (n = 8 mice for each treatment group). ***P < 0.001, two-tailed 
unpaired Student’s t-test. Data are represented as mean ± s.e.m. Immunoblots with the indicated 
antibodies of the PDX biopsies (one representative sample for each condition is shown). 
(C and D) Tumor volume quantification for patient derived (D) PDAC and (E) LAC xenografts 
modified to express sgRNA METTL13 or sgRNA Control (see Fig. S7A and S7B) treated with 
placebo (vehicle) or Omipalisib. Plots showing fold change in tumor volume compared to initial 
tumor volume. ***P < 0.001, n.s., not significant, two-tailed unpaired Student’s t-test. Data are 
represented as mean ± s.e.m. Treatment schedule as in Figure 7E. 
 
(E) Model of the role of METTL13 and eEF1A methylation in enhancing protein synthesis to 
fuel growth signal-driven tumorigenesis. 
 
(F and G) IMR90 (non-transformed), and the Ras positive HT1080, PaTu8902, T3M4 and 
colo357 cell lines were treated as indicated with SDS-1-021 for 72h. (F) Proliferation was 
determined by BrdU incorporation and expressed as a fraction of the inhibition of BrdU 
incorporation relative to control (vehicle-treated) cells. Results are presented as mean values ± 
SD (n = 3). (G) Viable cell count was measured by Trypan blue exclusion and expressed as a 
fraction of control (vehicle-treated) cells. Results are presented as mean values ± SD (n = 3). 
*p<0.05, **P < 0.01, two-tailed unpaired Student’s t-test.  
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Supplementary Table Legends  
 
Table S1. List of sgRNAs used in Gene-Editing Coupled Biochemical Screen; Related to 
Figure 1   
Table S2. List of Methylated Peptides Detected in SILAC-based Quantitative Proteomic 
Analysis; Related to Figure 3   
Table S3. List of Compounds used in Cell Growth Inhibition Screen; Related to Figure 7   
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